Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report)'s stock price rose 6.4% during trading on Monday . The stock traded as high as $19.66 and last traded at $19.36. Approximately 145,756 shares traded hands during trading, a decline of 62% from the average daily volume of 386,972 shares. The stock had previously closed at $18.20.
Analysts Set New Price Targets
KYTX has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They set an "overweight" rating and a $44.00 target price for the company. Leerink Partnrs restated an "outperform" rating on shares of Kyverna Therapeutics in a research note on Monday, March 4th. JPMorgan Chase & Co. began coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They issued an "overweight" rating and a $39.00 price objective for the company. Morgan Stanley began coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They issued an "overweight" rating and a $40.00 price objective for the company. Finally, SVB Leerink began coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They issued an "outperform" rating and a $48.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of "Buy" and an average price target of $42.75.
View Our Latest Analysis on KYTX
Kyverna Therapeutics Stock Performance
The company has a fifty day moving average price of $25.89.
Insider Transactions at Kyverna Therapeutics
In other news, major shareholder Northpond Ventures Iii Gp, Llc bought 450,000 shares of the stock in a transaction dated Monday, February 12th. The shares were acquired at an average price of $22.00 per share, with a total value of $9,900,000.00. Following the acquisition, the insider now owns 450,000 shares in the company, valued at $9,900,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
